⚠ Evidence warning: Clinical trials or other evidence do not support the claim that a sustained strict gluten-free diet reduces the lymphoma risk in dermatitis herpetiformis to background levels. This page keeps it as a report of what people, websites or other media say.
Dermatitis Herpetiformis
Dermatitis herpetiformis (DH) is an intensely itchy, chronic blistering skin disease caused by gluten sensitivity — the same immune mechanism that drives celiac disease. Although it presents on the skin, it is fundamentally a systemic autoimmune condition in which ingested gluten triggers immunoglobulin A (IgA) antibody deposits in the dermis, igniting blisters on the elbows, knees, buttocks, and scalp. A strict gluten-free diet is both the primary treatment and the only therapy that addresses the underlying disease rather than masking its symptoms.
Table of Contents
- Dermatitis Herpetiformis Explained
- Pathophysiology: The Gluten-IgA Connection
- Epidemiology and Risk Factors
- Clinical Features and Symptoms
- Diagnostic Approach
- Treatment: Gluten-Free Diet and Dapsone
- Monitoring and Long-Term Management
- Key Research Papers
- Related PubMed Searches
- Connections
- Featured Videos
Dermatitis Herpetiformis Explained
Dermatitis herpetiformis is the pathognomonic cutaneous manifestation of celiac disease — the skin expression of gluten-sensitive enteropathy. First described by Louis Duhring in 1884, it was long considered a purely dermatological condition until the 1960s and 1970s, when researchers established its inseparable connection to intestinal gluten intolerance and small bowel villous atrophy.
Despite its name, DH has no relationship to herpes viruses. The term "herpetiformis" refers only to the appearance of grouped (herpetiform) vesicles, which mimic the cluster pattern of herpesvirus skin lesions. The cause is entirely immunological, driven by gluten consumption in genetically susceptible individuals.
DH is classified as an autoimmune bullous (blistering) dermatosis. Unlike many other blistering diseases that affect the skin in isolation, DH reflects systemic gluten intolerance — meaning most patients have concurrent intestinal damage even when they have no digestive symptoms whatsoever. Treating only the skin without addressing the diet leaves the underlying celiac disease active and the patient at continued risk for long-term complications.
Pathophysiology: The Gluten-IgA Connection
The mechanism linking dietary gluten to skin blistering involves a multi-step autoimmune cascade that operates across both the gut and the skin simultaneously.
Step 1 — Gluten sensitization: In genetically susceptible individuals (those carrying HLA-DQ2 or HLA-DQ8 haplotypes), dietary gluten — specifically the gliadin component of wheat, rye, and barley — is incompletely digested in the small intestine. Tissue transglutaminase 2 (TG2) in the gut wall deamidates gliadin peptides, creating epitopes that are recognized as foreign by antigen-presenting cells bearing HLA-DQ2 or HLA-DQ8.
Step 2 — Dual antibody production: The adaptive immune response generates immunoglobulin A antibodies against two closely related enzyme targets. Anti-tissue transglutaminase 2 (anti-TG2) antibodies cause intestinal damage — the same antibodies found in classic celiac disease. Critically, the immune response also cross-reacts with epidermal transglutaminase 3 (TG3, eTG), a structurally related enzyme expressed in the skin. Anti-TG3 immunoglobulin A antibodies are the skin-specific autoantibody of DH and are the most diagnostically specific serum marker for this condition.
Step 3 — Dermal immunoglobulin A deposition: IgA-TG3 immune complexes circulate in the bloodstream and deposit in the papillary dermis — the uppermost layer of the dermis just beneath the epidermis, where small capillaries and collagen bundles project upward into the epidermal folds (dermal papillae). This deposition occurs at the tips of the dermal papillae and is independent of whether the skin is visibly inflamed.
Step 4 — Complement activation and neutrophil infiltration: The immunoglobulin A deposits activate complement via the alternative and lectin pathways, generating chemotactic fragments (C3a, C5a) that recruit neutrophils into the papillary dermis. Neutrophil accumulation at papillary tips releases proteolytic enzymes (including elastase and collagenase) that cleave the dermoepidermal junction, producing subepidermal fluid-filled blisters.
Key insight: The skin lesions are driven by the same gluten intake that damages the intestinal mucosa. Gluten elimination depletes the antigenic stimulus, stops new immunoglobulin A complex formation, and eventually allows existing deposits to clear — explaining why the gluten-free diet is the only true disease-modifying treatment.
Epidemiology and Risk Factors
DH has a pronounced Northern European predominance, reflecting the distribution of HLA-DQ2 and DQ8 haplotypes. In Finland — one of the most studied populations — a 40-year study from Tampere counted 75.3 people with DH per 100,000 in 2009, eight times fewer than people with celiac disease in the same area. In the United States the prevalence is estimated at approximately 1 in 10,000, though this likely underestimates true frequency due to underdiagnosis and delayed diagnosis averaging 10 or more years from symptom onset.
Sex distribution: Unlike celiac disease, which is approximately twice as common in women, DH shows roughly equal sex distribution, with some studies suggesting a slight male predominance; the Finnish 40-year study found a male-to-female ratio of 1.1 to 1. The reason for this difference is not fully understood but may relate to sex differences in skin immunoglobulin A trafficking.
Age of onset: DH can occur at any age. The average age at diagnosis has risen in recent decades: a 2018 review puts it at 40–50 years today, and in the Finnish 40-year study it rose in men from 35.3 to 51.1 years and in women from 36.3 to 45.8 years. Pediatric DH is recognized but uncommon. Late-onset DH in elderly patients is increasingly reported.
Genetic risk factors:
- HLA-DQ2 (encoded by HLA-DQA1*05 and HLA-DQB1*02): present in approximately 90–95% of DH patients
- HLA-DQ8 (encoded by HLA-DQA1*03 and HLA-DQB1*03:02): accounts for most of the remaining cases
- First-degree relatives of DH patients have significantly elevated risk of both DH and celiac disease
Associated autoimmune conditions: DH clusters with other organ-specific autoimmune diseases, consistent with shared human leukocyte antigen (HLA) haplotypes and immune dysregulation:
- Thyroid disease: Hashimoto's thyroiditis and Graves' disease — the most common associations, present in 10–15% of DH patients
- Type 1 diabetes mellitus
- Pernicious anemia (autoimmune gastritis with intrinsic factor antibodies)
- Systemic lupus erythematosus (SLE)
- Sjögren's syndrome
- Alopecia areata
Dietary triggers beyond classic gluten: Iodine intake can transiently worsen DH skin disease in some patients, possibly by exacerbating neutrophil recruitment at existing immunoglobulin A deposits, though iodine restriction is not routinely recommended. Oats represent a nuanced case — most DH patients can tolerate certified gluten-free oats once the disease is well controlled on a gluten-free diet; in a 1998 Finnish oat study the rash was not set off by eating oats (details under Monitoring and Long-Term Management).
Fewer new cases over time: DH is becoming less common even as celiac disease is diagnosed more often. In the Finnish 40-year study, new cases fell from 5.2 to 2.9 and then 2.7 per 100,000 people a year across three 10-year periods starting in 1980, a drop the authors contrasted with the rise in celiac disease. A 2018 review gives a yearly rate of 0.8 per 100,000 for the United Kingdom (U.K.).
Clinical Features and Symptoms
The clinical presentation of DH is distinctive but frequently misdiagnosed as eczema, scabies, or insect bites before the correct diagnosis is reached.
Pruritus as the defining symptom: DH produces one of the most intensely pruritic rashes in dermatology. The itch is characteristically described as burning and stinging rather than pure itch, and this burning sensation often precedes the appearance of visible lesions by hours. Patients frequently scratch lesions to the point of excoriation before they present to a physician, meaning intact vesicles are often absent at the time of clinical examination.
Primary lesion morphology: When intact, the primary lesion is a small tense vesicle (blister) arising on an erythematous base, grouped in clusters (hence "herpetiformis"). Papules and urticarial plaques also occur. Because vesicles are rapidly excoriated, the clinician more often sees:
- Erosions — denuded skin where vesicle roofs have been scratched off
- Excoriations — linear scratch marks
- Post-inflammatory hyperpigmentation — brown macules marking healed lesions
- Lichenification — thickened skin from chronic scratching
Distribution: DH has a strikingly symmetric, extensor-predominant distribution:
- Elbows — the single most common site, affected in the vast majority of patients
- Knees — second most common
- Buttocks and sacrum — very characteristic; buttock involvement alone raises the possibility of DH
- Posterior scalp and hairline
- Shoulders and upper back
- Anterior scalp and neck — less commonly
The face and mucous membranes are rarely involved, distinguishing DH from pemphigus vulgaris. Palms and soles are generally spared.
Gastrointestinal involvement: Approximately 90% of DH patients have villous atrophy on duodenal biopsy — the same finding seen in classic celiac disease. However, only about 20% have overt gastrointestinal symptoms (diarrhea, bloating, abdominal pain). The majority of DH patients have subclinical celiac enteropathy: histological intestinal damage that is silent because the compensatory mucosal surface area of the small intestine masks nutritional deficiency. This fact is clinically important — a DH patient who denies gastrointestinal (GI) symptoms still has active celiac disease and still requires a gluten-free diet.
Nutritional consequences of silent celiac disease: Even without overt gastrointestinal symptoms, DH patients may present with iron-deficiency anemia (most common), folate deficiency, vitamin B12 deficiency (less common, as terminal ileum is usually spared), osteoporosis, and neurological sequelae.
Diagnostic Approach
The diagnosis of DH rests on skin biopsy with direct immunofluorescence (DIF). This is the gold-standard test. Serology provides supportive evidence and is useful for monitoring, but cannot substitute for histopathology in establishing the diagnosis.
Skin biopsy — site selection is critical: The biopsy is taken from perilesional skin — normal-appearing skin immediately adjacent to (within 1 cm of) an active lesion. Biopsy of the lesion itself is diagnostically unreliable: the blister and surrounding intense inflammation obscure the characteristic immunoglobulin A deposits and produce a nonspecific picture. Perilesional skin, which appears normal to the naked eye, harbors the diagnostic immunoglobulin A deposits without inflammatory artifact.
Direct immunofluorescence (DIF): The perilesional biopsy is processed in Michel's transport medium (not formalin) and examined by immunofluorescence microscopy. The pathognomonic finding is granular immunoglobulin A deposits in the dermal papillae. This granular (particulate) immunoglobulin A staining pattern distinguishes DH from Linear immunoglobulin A Bullous Dermatosis, which shows a linear band of immunoglobulin A at the dermoepidermal junction. Fibrin and C3 complement fragments are also commonly seen at papillary tips. Immunoglobulin G (IgG) and immunoglobulin M (IgM) deposits are absent or minimal.
Serology:
- Anti-TG3 immunoglobulin A (anti-epidermal transglutaminase) — the most specific serum marker for DH; not yet universally available but increasingly offered by reference laboratories
- Anti-TG2 immunoglobulin A (anti-tissue transglutaminase) — elevated in the majority of DH patients; the same test used to diagnose celiac disease; normalizes with sustained gluten-free diet and is useful for monitoring dietary compliance
- Anti-endomysial immunoglobulin A (EMA) — highly specific for celiac/DH spectrum; test is expensive and observer-dependent
- Anti-deamidated gliadin peptide (DGP) IgA — useful when total immunoglobulin A deficiency is suspected (immunoglobulin A-deficient patients produce immunoglobulin G class antibodies instead)
- Total serum immunoglobulin A — measure to rule out immunoglobulin A deficiency; immunoglobulin A-deficient patients (prevalence ~1:300) will have false-negative immunoglobulin A-based serology and require immunoglobulin G-class antibody testing
Duodenal biopsy: Gastroenterological evaluation with upper endoscopy and duodenal biopsy can demonstrate Marsh grade 2–3 villous atrophy, confirming the celiac enteropathy that underlies DH. Duodenal biopsy is not required for the DH diagnosis when DIF is positive and clinical presentation is consistent, but is often performed to document the extent of intestinal disease and to establish a baseline for monitoring.
Differential diagnosis:
- Linear immunoglobulin A Bullous Dermatosis — clinically similar but shows linear (not granular) immunoglobulin A on DIF; often drug-induced (vancomycin, nonsteroidal anti-inflammatory drugs (NSAIDs)); not gluten-related
- Bullous Pemphigoid — subepidermal blisters but immunoglobulin G (not immunoglobulin A) deposits; linear pattern; typically elderly patients
- Pemphigoid Gestationis — pregnancy-associated; linear C3 and immunoglobulin G
- Scabies — intensely pruritic; burrows; mite/eggs on scraping
- Atopic Dermatitis — flexural distribution, negative DIF, no immunoglobulin A deposits
Treatment: Gluten-Free Diet and Dapsone
Management of DH combines a disease-modifying dietary intervention (gluten-free diet) with a symptom-suppressing drug (dapsone) used as a bridge while the diet takes effect.
Gluten-Free Diet (GFD)
The GFD is the primary and definitive treatment for DH. It is the only intervention that addresses both the skin disease and the underlying intestinal celiac damage simultaneously. Key points:
- What to eliminate: All sources of gluten — wheat (including spelt, kamut, durum, semolina, farro), barley, rye, and triticale. Gluten-free diets use certified gluten-free oats because ordinary oats are often mixed with wheat, barley or rye during growing and milling.
- Time to skin remission: Unlike dapsone, which works within 48 hours, the GFD requires 1–2 years of strict adherence before the skin disease is fully suppressed. Immunoglobulin A deposits in the dermis clear slowly — DIF IgA deposits may persist for 2 or more years even with perfect dietary compliance.
- Strictness required: The threshold for DH is very low — even traces of gluten (from cross-contamination, shared cooking surfaces, unlabeled additives) can perpetuate disease. Dietitians experienced with celiac disease teach where these hidden sources of gluten occur.
- Gut healing: Villous atrophy in the duodenum begins recovering within weeks of strict GFD and typically normalizes within 1–2 years in adults (faster in children).
- Dapsone dose reduction: As the GFD takes effect, dapsone requirements typically decline and can often be discontinued after 1–2 years in patients maintaining strict dietary compliance.
Dapsone (Diaminodiphenyl Sulfone)
Dapsone is the primary pharmacological therapy for DH. It produces dramatic symptomatic relief but does not modify the underlying disease:
- Mechanism: Dapsone inhibits neutrophil chemotaxis, reduces neutrophil oxidative burst, and suppresses immunoglobulin A-mediated complement activation in the skin — suppressing the inflammatory cascade that produces blisters without eliminating the cause (immunoglobulin A deposits).
- Speed of response: Symptoms typically begin to improve within 24–48 hours of initiating dapsone. This rapid response both provides relief and serves as a quasi-diagnostic test — a dramatic response to dapsone in a patient with the right clinical picture strongly supports the DH diagnosis.
- Dosing: Treatment usually starts at 25–50 mg/day and is adjusted to the lowest effective dose, typically 25–200 mg/day depending on disease severity. Lower doses suffice as the GFD takes effect.
- Monitoring requirements:
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency screen before starting — dapsone causes oxidative hemolysis; glucose-6-phosphate dehydrogenase-deficient patients are at high risk of severe hemolytic anemia from dapsone
- Complete blood count (CBC) — checks for dose-dependent hemolytic anemia (universal, even in glucose-6-phosphate dehydrogenase-normal patients at higher doses) and agranulocytosis (rare but serious)
- Methemoglobin levels — dapsone produces methemoglobin; methemoglobinemia is dose-dependent; symptomatic methemoglobinemia is treated with methylene blue 1–2 mg/kg intravenous (IV)
- Liver function tests — hepatotoxicity occurs rarely
- Peripheral neuropathy — with long-term high-dose use
Alternative Agents for Dapsone-Intolerant Patients
When dapsone is contraindicated (glucose-6-phosphate dehydrogenase deficiency, allergy, intolerance), alternatives include:
- Sulfapyridine — second-line sulfonamide; less effective than dapsone; monitoring for hemolysis and agranulocytosis required
- Colchicine — inhibits neutrophil motility; modest efficacy
- Tetracycline + niacinamide — combination with anti-neutrophil properties; used in patients unable to tolerate sulfonamide drugs
Topical steroids and antihistamines provide minimal relief for the intense itch of DH and are not considered adequate monotherapy.
Monitoring and Long-Term Management
DH requires lifelong management because the underlying gluten sensitivity does not resolve. With sustained strict dietary adherence, however, most patients achieve complete skin remission and significantly reduce their cancer risk.
Laboratory monitoring:
- Anti-TG2 immunoglobulin A and/or anti-TG3 immunoglobulin A — recheck at 6 and 12 months after GFD initiation, then annually. Normalization confirms dietary compliance and predicts eventual skin remission. Persistently elevated antibodies indicate continued gluten exposure, even if the patient believes they are compliant.
- Complete blood count and methemoglobin — every 3–6 months while on dapsone
- Iron studies, folate, B12, vitamin D, bone density (DEXA) — screen at diagnosis and periodically, as malabsorption from subclinical celiac disease may have been ongoing for years
Long-term cancer risk: Untreated or poorly controlled celiac disease — including the subclinical celiac disease of DH — is associated with a modestly elevated risk of lymphoma (a cancer of the immune cells). In a Finnish study of 1,104 people diagnosed with DH between 1969 and 2001, 11 (1%) developed lymphoma 2–31 years after diagnosis. Most were B-cell lymphomas (8 of the 11); 2 were enteropathy-associated T-cell lymphoma (EATL), the lymphoma most linked with celiac disease, which arises from chronically activated intraepithelial T lymphocytes in the setting of persistent gut inflammation; 1 could not be classified. The absolute risk of this lymphoma is low (estimated 5–7 per 100,000 patient-years), but it is meaningfully higher than the general population. Sustained strict gluten-free diet appears to reduce this risk to background levels. The 11 patients with lymphoma had kept to the gluten-free diet significantly less strictly than matched DH patients without lymphoma. Among 1,825 of the patients' parents, siblings and children, 3 (0.2%) developed lymphoma, all B-cell type. A 2018 Finnish review reported that the long-term outlook of DH patients on a gluten-free diet is excellent, with a death rate even lower than that of the general population. Non-responsive or refractory disease is the setting in which gastroenterologists carry out endoscopic checks of gut healing and look for lymphoma.
A 2026 United States study: Researchers using a large U.S. health-records database compared 6,896 adults with DH (average age 53) identified between 2005 and 2025 with matched people who had neither celiac disease nor DH. During follow-up 8.36% of the DH group died against 6.54% of the comparison group (adjusted hazard ratio 1.25). The DH group also had more major heart and blood-vessel events (hazard ratio 1.22) and about 2.6 times the rate of non-Hodgkin lymphoma (hazard ratio 2.58). The study abstract does not report the results by whether people kept a gluten-free diet.
Pregnancy and DH: DH can worsen, improve, or remain unchanged during pregnancy. The GFD is continued through pregnancy. Dapsone was listed as U.S. Food and Drug Administration (FDA) pregnancy category C under the older letter system, which the FDA has since replaced in drug labels with a written risk summary; it is often continued during pregnancy when the benefit is judged to outweigh the risk, with obstetric care involved. Dapsone exposure before birth can cause hemolytic anemia in the newborn, which is why exposed newborns are checked for it.
Children and adolescents: DH in children requires particularly attentive dietary counseling, as school environments (cafeterias, shared snacks) create constant cross-contamination risk. Untreated celiac enteropathy significantly slows growth, which is why children's growth and nutrition are tracked closely.
Reintroduction of oats: In practice, certified gluten-free oats are usually introduced cautiously after at least 1–2 years of stable, well-controlled disease on a GFD, under supervision, with clinical reassessment at 6 months. In a 1998 Finnish study, 11 DH patients in remission on a gluten-free diet ate 50 g of oats every day for six months: 8 stayed free of symptoms, 2 had a short-lived rash and 1 left the study because of a mild but more lasting rash. Three of 11 comparison patients who ate no oats also had a short-lived rash. A blood marker of celiac activity (IgA endomysial antibodies) stayed negative in everyone, and biopsies showed no change in the small-bowel lining. The authors concluded that the rash in DH is not set off by eating oats. The main gluten risk with oats comes from wheat, barley or rye mixed in with ordinary oats, not from the oats themselves.
Key Research Papers
- Bolotin D, Petronic-Rosic V. "Dermatitis herpetiformis. Part I. Epidemiology, pathogenesis, and clinical presentation." J Am Acad Dermatol. 2011;64(6):1017–1024. — PubMed PMID: 21571167
- Antiga E, Caproni M. "The diagnosis and treatment of dermatitis herpetiformis." Clin Cosmet Investig Dermatol. 2015;8:257–265. — PubMed PMID: 25999753
- Reunala T, Salmi TT, Hervonen K, et al. "Dermatitis Herpetiformis: A Common Extraintestinal Manifestation of Coeliac Disease." Nutrients. 2018;10(5):602. — PubMed PMID: 29757210
- Salmi TT, Hervonen K, Kautiainen H, et al. "Prevalence and incidence of dermatitis herpetiformis: a 40-year prospective study." Br J Dermatol. 2011;165(2):354–359. — PubMed PMID: 21517799
- Zone JJ. "Skin manifestations of celiac disease." Gastroenterology. 2005;128(4 Suppl 1):S87–91. — PubMed PMID: 15825132
- Caproni M, Antiga E, Melani L, et al. "Guidelines for the diagnosis and treatment of dermatitis herpetiformis." J Eur Acad Dermatol Venereol. 2009;23(6):633–638. — PubMed PMID: 19470076
- Hervonen K, Hakanen M, Kaukinen K, et al. "First-degree relatives are frequently affected in coeliac disease and dermatitis herpetiformis." Scand J Gastroenterol. 2002;37(1):51–55. — PubMed PMID: 11843035
- Reunala T, Collin P, Holm K, et al. "Tolerance to oats in dermatitis herpetiformis." Gut. 1998;43(4):490–493. — PubMed PMID: 9824575
- Sugai E, Vazquez H, Nachman F, et al. "Accuracy of testing for antibodies to synthetic gliadin-related peptides in celiac disease." Clin Gastroenterol Hepatol. 2006;4(9):1112–1117. — PubMed PMID: 16860613
- Fry L, Seah PP, Harper PG, et al. "The small intestine in dermatitis herpetiformis." J Clin Pathol. 1974;27(10):817–824. — PubMed PMID: 4426977
- Collin P, Reunala T, Rasmussen M, et al. "High incidence and prevalence of adult coeliac disease. Augmented diagnostic approach." Scand J Gastroenterol. 1997;32(11):1129–1133. — PubMed PMID: 9399394
- Sárdy M, Kárpáti S, Merkl B, et al. "Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis." J Exp Med. 2002;195(6):747–757. — PubMed PMID: 11901200
- Hervonen K, Vornanen M, Kautiainen H, Collin P, Reunala T. "Lymphoma in patients with dermatitis herpetiformis and their first-degree relatives." Br J Dermatol. 2005;152(1):82–86. — PubMed PMID: 15656805
- Ludvigsson JF, Dagher J, Lebwohl B, Yao J, Green PHR, Ludwig RJ, Curman P. "Mortality, cardiovascular disease, and cancer in coeliac disease and dermatitis herpetiformis: a matched cohort study." Lancet Reg Health Am. 2026;60:101512. — PubMed PMID: 42256615
Related PubMed Searches
- Dermatitis herpetiformis treatment
- Dermatitis herpetiformis dapsone gluten-free diet
- Dermatitis herpetiformis immunoglobulin A direct immunofluorescence diagnosis
- Epidermal transglutaminase TG3 dermatitis herpetiformis
- Celiac disease skin manifestations autoimmune
Connections
- Dermatology
- Dermatitis Herpetiformis: Celiac of the Skin — the same disease approached as celiac disease and written for patients — why the biopsy is so often taken from the wrong spot, what dapsone will and will not do, and iodine as an under-recognised flare trigger.
- Celiac Disease
- Epidermolysis Bullosa
- Pemphigoid Gestationis
- Linear Immunoglobulin A Bullous Dermatosis
- Hashimoto's Thyroiditis
- Gastroenterology